MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...

AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...

Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...

Nov. 6, 2024 — Sewage surveillance is emerging as a powerful tool in the fight against antimicrobial resistance with the potential to protect vulnerable communities more ... Nov. 6, 2024 ...

Maryland’s biotech industry plays a pivotal role in advancing global health initiatives. This vibrant sector is characterized ...

Executive Vice President, R&D, MedImmune, Gaithersburg, Maryland, USA. Prior to joining Medimmune in 2001, Peter Kiener, D. Phil., spent 18 years with the Pharmaceutical Research Division of ...

Nov. 7, 2024 — Plastic pollution exacerbates the impacts of all planetary boundaries, including climate change, ocean acidification and biodiversity loss, a new paper shows. Ahead of the final ...

Following a 20-year career as a commissioned officer in the United States Army, including the last six years as chairman of the Department of Immunology at the Walter Reed Army Institute of Research, ...

Cancer is on course to be the leading cause of death in the EU by 2035. Europe's population is ageing rapidly, and obesity ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

Foreign leaders have rushed to ingratiate themselves with Donald J. Trump in recent days, nervously recalling the clashes, insults and feuds of his first presidency. By Mark LandlerMatina Stevis ...